Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Stephanie L, Van Bebber"'
Publikováno v:
Personalized medicine. 3(4)
A major challenge to adoption of personalized medicine approaches, such as pharmacogenomics, is that data to address many critical questions relevant to clinical application, economics, policy and regulation are typically unavailable or widely disper
Publikováno v:
Personalized medicine. 3(4)
BiDil
Publikováno v:
Journal of the National Comprehensive Cancer Network. 9:13-25
Predictive and prognostic biomarkers offer the potential for personalized therapy in oncology. Despite a multitude of publications in the oncology literature identifying potential biomarkers, however, only a select few are recommended for use in clin
Autor:
Stephanie L. Van Bebber, F. Reed Johnson, Kathryn A. Phillips, Nathalie A. Kulin, Judith M. E. Walsh, John Marshall, Semra Ozdemir, Deborah A. Marshall
Publikováno v:
Health Economics. 18:1420-1439
Background: Patient preferences can affect colorectal cancer (CRC) screening test use. We compared utility-based preferences for alternative CRC screening tests from a stated-preference discrete-choice survey of the general population and physicians
Autor:
Su-Ying Liang, Deborah A. Marshall, Kathryn A. Phillips, Judith M. E. Walsh, Nathalie A. Kulin, Stephanie L. Van Bebber
Publikováno v:
Personalized Medicine. 4:341-350
Objectives: Personalized medicine using genetic information is increasing in cancer screening and treatment; however, little is known about perceived value of genetic testing for cancer risk in a general population. The objectives of this report are:
Autor:
Stephanie L. Van Bebber, Mika Nagamine, David A. Lieberman, Karla Kerlikowske, Robert A. Hiatt, Su-Ying Liang, Jennifer S. Haas, Uri Ladabaum, Kathryn A. Phillips
Publikováno v:
Medical Care. 45:160-167
A major health priority is to increase colorectal cancer screening, and colonoscopy has become an increasingly important method of screening. The Medicare program began coverage for colonoscopy for average risk individuals in 2001.We sought to examin
Autor:
Tracy Durgin, Paul Wicks, John D. Hixson, Stephanie L. Van Bebber, Karen Parko, Arianne Graham, Deborah E. Barnes
Publikováno v:
Neurology, vol 85, iss 2
Hixson, JD; Barnes, D; Parko, K; Durgin, T; Van Bebber, S; Graham, A; et al.(2015). Patients optimizing epilepsy management via an online community: The POEM Study. Neurology, 85(2), 129-136. doi: 10.1212/WNL.0000000000001728. UCSF: Retrieved from: http://www.escholarship.org/uc/item/70x2f92h
Hixson, JD; Barnes, D; Parko, K; Durgin, T; Van Bebber, S; Graham, A; et al.(2015). Patients optimizing epilepsy management via an online community: The POEM Study. Neurology, 85(2), 129-136. doi: 10.1212/WNL.0000000000001728. UCSF: Retrieved from: http://www.escholarship.org/uc/item/70x2f92h
© 2015 American Academy of Neurology. Objective: The study objective was to test whether engaging in an online patient community improves self-management and self-efficacy in veterans with epilepsy. Methods: The study primary outcomes were validated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10a1addce35b778563effa2d186c3da5
https://escholarship.org/uc/item/70x2f92h
https://escholarship.org/uc/item/70x2f92h
Publikováno v:
Military medicine. 180(4)
Online tools for managing chronic health conditions are becoming increasingly popular. Perceived benefits include ease of use, low costs, and availability but are contingent on patient engagement, Internet access, and digital literacy. This article d
Publikováno v:
Personalized Medicine. 3:415-419
Third Wave’s Invader® UDP glucuronosyltransferase 1A1 (UGT1A1) Molecular Assay, a genotyping system to predict adverse drug reactions in patients receiving the chemotherapeutic agent irinotecan (Camptosar®, Pzifer, NY, USA) for the treatment of m
Publikováno v:
Personalized Medicine. 3:421-427
BiDil®(hydralazine and isosorbide dinitrate) represents an interesting application of personalized medicine – the first pharmaceutical specifically approved by a regulatory agency, the US FDA, for an indication in a particular population based on